Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It wil be wonderful when the CTLM is available in the USA
Progress toward re-submitting a PMA application during Fiscal Year 2012 and the beginning months of Fiscal Year 2013 was significantly delayed and then eventually halted simply due to lack of funding
The forum for this process is generally referred to as an FDA “Pre- IDE” meeting (essentially a pre-clinical meeting) between the Company, its FDA Consultants and the FDA/PMA Examiners. During the “Pre-IDE” meeting, the Company (and its FDA Consultants) would present their approach for both data collection, patient selection and data analysis. The FDA Reviewers would provide input (critique and suggestions) to us as to what they believe an acceptable PMA protocol would require. Once agreement is reached by all parties the next logical step is to implement the protocol. .
The average De Novo application took 482 days to be reviewed compared to the average PMA review of 284 days.
As of August 1, 2012, there were issued and outstanding 3,845,518,607 shares of our Common Stock
The number of shares outstanding of each of the issuer’s classes of common stock, as of October 10, 2012, was 7,287,218,961
No proof but I am confident this is the case
With 3000 shareholders, there's no hedge fund involvment, lmao.
That sounds about right;
What really happened is Grable and her daughter Deb went out for Chinese food, and the kiddies on the board in their usual fashion thought they went to China. lmao
I didn't say Grable lied. I said she didn't say it. Like I said, you have to look at all the below claims that have been repeatedly proven false;
- No dilution. Period
- Non-toxic financing complete
- PMA in process
Oh, and the list goes on.
That's about right, lol.
Lol. Heard that before, several times, and all thats happened is the PPS has dropped and the OS increased.
Truth is, Mrs Grable never said it in the first place, lol. Just like false claims of no dilution, non-toxic financing being done, and PMA in process. All false per the last 10K.
The whole trip to China was created on a message board. We've heard it before, lol. Ya know the claims of no dilution, financing done, and so on. No one believes any of that anymore.
they are about to lose everything.
They are broke, have no sales, and are forced to make cuts. Doesn't take digging. Just a quick 10K scan will show you that.
If anything happened even remotely close to your claims, you would already have details. Reporting company remember, lmao.
No buyout or merger, and can't afford insurance.
Wrong again Squeak. The 10K clearly states they dropped it due to costs and will "self-insure". Youre dealing with a fully reporting company, and if someone else was taking care of liability insurance, that section in the filing would have stated that. It didn't. Therefore, they are broke and dropped it. No way to spin that 10K as positive. It's the worse one yet, and we apparently agree on that, since I haven't seen any positive sections posted, lol.
Also, this merger/buy-out talk is pretty funny. Everyone knows, including you, that Mrs Grable owns the key patents. They are to sell for her benefit only, but you knew that already.
You have a shell company who has a patent "agreement", which can be yanked at any time. They don't "own" anything of much value, as can be seen by the weak asset column on the 10K.
Companies do not drop product liability insurance period!
As part of our cost savings initiatives, we cancelled the policy as we have not had any adverse experiences after conducting more than 25,000 patient scans worldwide. We have assumed the risk of product liability. A successful product liability claim against us could have a material adverse effect on the Company. Furthermore, there can be no assurance that, in the future, we will be able to obtain adequate or maintain product liability insurance on acceptable terms.
Funding via dilution only as stated in the 10K, and signed by Grable.
Nothing to merge with. You do realize the company has to actually own something to be bought out? The main patents are Mrs. Grables. They don't belong to IMDS, which is also clearly stated in the 10K.
You really gotto read that thing. It's full of valuable info.
The 10K was released yesterday. You still haven't read it? Nothing points to a merger and the funders don't want it. After converting, they dump the shares as quickly as possible. Regardless, no merger or buy-out would benefit IMDS or shareholders. Mrs. Grable holds the main patents. From the 10K;
We depend on third-party licensing agreements for patents and software without which our operations may be curtailed.
All that means to me is that a merger has taken place
.0001s a dumping and folks still buying .0002s. Must be the non-10K readers loading up, lol.
Squeak, the dilution is ongoing, and the funding hasn't been dealt with. Per yesterday's 10-K, funding via dilution will continue. Oh yeah, the PMA process for application to FDA has been halted through next year. Period.
Look at this dilution. It's massive. Period.
The number of shares outstanding of each of the issuer’s classes of common stock, as of September 20, 2011 was 985,468,507.
The number of shares outstanding of each of the issuer’s classes of equity as of February 17, 2012: 1,458,049,852 shares of common stock,
The number of shares outstanding of each of the issuer’s classes of equity as of May 18, 2012: 2,422,630,676 shares of common stock
As of August 1, 2012, there were issued and outstanding (i) 3,845,518,607 shares of our Common Stock
The number of shares outstanding of each of the issuer’s classes of equity as of October 10, 2012, was 7,287,218,961.
squeak1 Member Profile
Monday, July 23, 2012 7:52:47 PM
Re: LongnShortOfIt post# 21180
Post # of 29580
The funding has been dealt with period
There is no dilution period
And I repeat that if by the end of the week all these old problems and that's what they are OLD PROBLEMS have not been addressed with the upcoming news then I will eat my words and never post here again rofl
The future for imds is here!
The CTLM is being actively advertised and orders are coming in that will blow every bodies mind that are invested here!
Imds is destined for penny land real soon and dollar land also.
See if I am wrong!
Did you read the 10K yet? I'll break it down for you;
-Still diluting, massively, with over 7 billion in the OS
-PMA is halted
-No sales in the 4th quarter
-Still no approval in Australia or Mexico
-Will still dilute to pay bills.
From the 10K;
In fiscal 2010, fiscal 2011, fiscal 2012 and thus far in fiscal 2013, we have used the proceeds from short-term loans, long-term loans and proceeds from our Southridge Private Equity Credit Agreement for working capital. Going forward we intend to use the proceeds from short term and long term loans and issuance of convertible preferred stock, as our sources of working capital. We may also seek to raise fund through our Private Equity Credit Agreement with Southridge which requires an effective S-1 Registration Statement. Substantial additional financing will be required before and after receipt of FDA marketing clearance, assuming it is received, as to which there can be no assurance.
Devcool
Friday, June 22, 2012 9:48:46 AM
Re: ~ Blue ~ post# 11263
Post # of 29580
6 REASONS WHY IMDS WILL BE TRADING AT $5-10/SHARE IN A YEAR:
- 35 patents capable of GLOBAL monopoly. 20 USA and 15 INTL. JUST 1 of their patents accounts for the CTLM's ability to detect cancer through dense tissue and implants...NO OTHER TECHNOLOGY IN THE WORLD CAN DO THIS! Dense tissue extends into the brain, lungs, etc. and therefore the laser optical imaging technology will be enhancing virtually ALL aspects of the medical diagnostics field!
- 16 distributors in 16 countries ALREADY...not to mention pending Russia approval! They also have FDA EXPORT CERTIFICATION, CE MARKETING (32 countries in Europe), and CHINA approval
- Shimadzu Medical signed on as a distributor, and JUST YESTERDAY updated their website confirming business relationships
http://www.shimadzumedical.com.au/imaging-diagnostic-distribution-agreement-.html
- Each CTLM sells at a retail price of $495,000 each...the product will monopolize the global mammography market.
- Upon securing non-toxic funding, the company will be immediately applying to the FDA, and the approval will be received BEFORE the usual 90 day review window. During this period, there will most likely be immediate distribution through Shimadzu Medical to New Zealand and the Pacific Islands. Distribution to Australia will occur as soon as possible as well, and stockprince's email with the company showed that the application to Australia for approval of the CTLM has ALREADY BEEN SUBMITTED BY SHIMADZU MEDICAL OCEANIA...before the FDA process is even complete you're looking at MULTI-MILLIONS on revenue that should be apparent on the Q2.
- The breast mammogram market in the USA is controlled by only 4 COMPANIES!! ALL WITH DATED TECHNOLOGY, AND HAZARDOUS!! THE CTLM DOESN'T USE X-RAYS or any other hazardous particle, and no longer needs to squeeze the breast. YOU'RE LOOKING AT PATIENT SATISFACTION, SAFETY, and NO UN-NEEDED BIOPSIES as it has been CLINICALLY PROVEN the CTLM is up to 90% more effective than anything on the market TODAY!
"In a study of over 100 women, including 30 with breast cancer, optical imaging increased sensitivity and specificity of breast cancer detection by more than 90% (Britton Chance, Molecular Imaging, Vol. 2 #2)"
http://www.imds.com/ctlm/
There are 10,000 mammogram centers in the USA alone, each machine sells at a retail price of $495,000 each...now...think of the rest of the world and you do the math $5-10/share in a year folks, in the first year alone IMDS will exceed a billion in revenue
Progress toward re-submitting a PMA application during Fiscal Year 2012 and the beginning months of Fiscal Year 2013 was significantly delayed and then eventually halted simply due to lack of funding to hire the necessary FDA consultants required to assist in the process.
During fiscal 2012, a significant reduction in operating overhead/expenses occurred due to the reduction in key staff. This reduction in staff halted any progress towards getting the PMA application started as a result of our financial and funding limitations.
Yep, today's 10k brought the crickets back, lol. That's the bad part of creating positive hype on a reporting company. You only have around 3 months between financial filings to create positive spin. Then a filing is released and proves all the positive spin false.
Hey guys look up china on this list
Then tell me no good news lol
I read that too and chuckled. I guess insuring 6 figure salaries is more important than insuring their product. They are in bad shape, and the future looks even worse.
Yes, the 10K is horrific without a single positive development.
Yes, the 10K is horrific without a single positive development.
Yeah, okay. What happened to all the sales? What happened to Australian and Mexican approvals? What about the PMA? You say "necessary" dilution. What was it for?
The 10K was being hyped as huge news coming, all day. Then, it's released, is very negative, and it is now called old news, lol.
Yep, I underestimated it for sure. I was thinking 6 bil, with 6.5 bil worse case.
You've had news 2 times in the last 3 months. It didn't move the stock either time.
Earlier, you referred to this "past" report as great news coming. Why the change?
That was the past in app 212 pages
Wow, look at this. Progress on the PMA has been halted into 2013;
Progress toward re-submitting a PMA application during Fiscal Year 2012 and the beginning months of Fiscal Year 2013 was significantly delayed and then eventually halted simply due to lack of funding to hire the necessary FDA consultants required to assist in the process. Our employees have reached their level of FDA expertise related to preparing the “ground work” for a PMA application submission and can proceed no further without the expert assistance of FDA consultants.
Well, I know one definite thing, today's 10K sure has proven much of the positive spin hype false. No sales in 4th quarter, massive dilution, no Australian or Mexican approvals, and no FDA progress or even a start.
Oh yeah, and toxic financing is still ongoing.
In October 2012, we received $30,000 from Panache pursuant to a short-term promissory note.
In October 2012, we received $38,500 from FLUX Carbon Starter pursuant to a short-term promissory note.
In October 2012, we received $27,000 from Southridge pursuant to a short-term promissory note
7.2 billion OS as of last Wednesday. It was 3.8 billion in August. They are diluting over a billion per month. Another AS increase on the way.
It will be hard for the CTLM to overcome, when they haven't even started the PMA process, per today's filing.
It's news alright. I thought 6 - 6.5 billion OS, but it's 7.2 billion. They diluted 3.4 billion in 2 months. Looks like another AS increase within 2 months at this rate.
The number of shares outstanding of each of the issuer’s classes of common stock, as of October 10, 2012, was 7,287,218,961
Here's some of those nasty .00005 debt conversions;
On October 3, 2012, SGI Group executed a partial debt to equity conversion of the $30,000 short-term promissory note originally dated August 25, 2011 and purchased on August 20, 2012 from Southridge, in which they converted $9,000 principal and $106 in interest. We issued SGI Group 182,124,200 common shares pursuant to Rule 144 based on an agreed conversion price of $0.00005 per share.
On October 4, 2012, Panache executed a partial debt to equity conversion of a $25,000 short-term promissory note dated February 28, 2012 in which they converted $6,600 principal. We issued Panache 120,000,000 common shares pursuant to Rule 144 based on an agreed conversion price of $0.000055 per share.
What about all these sales you were claiming? Per the revenue numbers, there has been no increase from March to June 2012. No sales in 4th quarter.
And it's nasty
Here are the most recent conversions;
On September 5, 2012, Southridge executed a partial debt to equity conversion of a $100,000 short-term promissory note dated September 28, 2011 in which they converted $85,582 principal. We issued Southridge 380,363,446 common shares pursuant to Rule 144 based on an agreed conversion price of $0.00023 per share.
On September 10, 2012, Levin Consulting Group executed a partial debt to equity conversion of the $70,000 short-term promissory note originally dated August 25, 2011 and purchased on August 20, 2012 from Southridge, in which they converted $20,000 principal. We issued Levin Consulting Group 80,000,000 common shares pursuant to Rule 144 based on an agreed
conversion price of $0.00025 per share. On September 21, 2012 we issued Levin Consulting Group an additional 120,000,000 shares because the closing bid price on the clearing date fell below the Initial closing bid price.
On September 10, 2012, Panache executed a partial debt to equity conversion of a $100,000 short-term promissory note dated August 25, 2011 in which they converted $14,885 principal. We issued Panache 80,026,882 common shares pursuant to Rule 144 based on an agreed conversion price of $0.000186 per share.
On September 11, 2012, Southridge executed a final debt to equity conversion of a $100,000 short-term promissory note dated September 28, 2011 in which they converted $10,418 principal and $3,004 in interest. We issued Southridge 89,478,883 common shares pursuant to Rule 144 based on an agreed conversion price of $0.00015 per share.
On September 11, 2012, Southridge executed a partial debt to equity conversion of a $100,000 short-term promissory note dated October 26, 2011 in which they converted $32,500 principal and $7,036 in interest. We issued Southridge 263,570,776 common shares pursuant to Rule 144 based on an agreed conversion price of $0.00015 per share.
On September 12, 2012, Southridge executed a partial debt to equity conversion of a $100,000 short-term promissory note dated October 26, 2011 in which they converted $4,150 principal. We issued Southridge 27,666,667 common shares pursuant to Rule 144 based on an agreed conversion price of $0.00015 per share.
On September 12, 2012, Panache executed a partial debt to equity conversion of a $40,000 short-term promissory note dated November 21, 2011 in which they converted $23,250 principal. We issued Panache 125,000,000 common shares pursuant to Rule 144 based on an agreed conversion price of $0.000186 per share.
On September 19, 2012, Panache executed a final debt to equity conversion of a $40,000 short-term promissory note dated November 21, 2011 in which they converted $16,750 principal and $3,244 in interest. We issued Panache 128,991,484 common shares pursuant to Rule 144 based on an agreed conversion price of $0.000155 per share.
On September 20, 2012, Southridge executed a partial debt to equity conversion of a $100,000 short-term promissory note dated October 26, 2011 in which they converted $47,300 principal and $153 in interest. We issued Southridge 379,627,369 common shares pursuant to Rule 144 based on an agreed conversion price of $0.000125 per share.
On September 27, 2012, OTC Global Partners executed a partial debt to equity conversion of the $30,000 short-term promissory note in which they converted $18,000 in principal. We issued OTC Global Partners 180,000,000 common shares pursuant to Rule 144 based on an agreed conversion price of $0.0001 per share.
On September 28, 2012, Panache executed a partial debt to equity conversion of a $25,000 short-term promissory note dated February 28, 2012 in which they converted $13,200 principal. We issued Panache 120,000,000 common shares pursuant to Rule 144 based on an agreed conversion price of $0.00011 per share.
On October 1, 2012, Southridge executed a final debt to equity conversion of a $100,000 short-term promissory note dated October 26, 2011 in which they converted $16,050 principal and $219 in interest. We issued Southridge 162,691,781 common shares pursuant to Rule 144 based on an agreed conversion price of $0.0001 per share.
On October 1, 2012, Southridge executed a partial debt to equity conversion of a $20,000 short-term promissory note dated November 14, 2011 in which they converted $10,900 principal and $1,398 in interest. We issued Southridge 122,983,562 common shares pursuant to Rule 144 based on an agreed conversion price of $0.0001 per share.
On October 2, 2012, Southridge executed a final debt to equity conversion of a $20,000 short-term promissory note dated November 14, 2011 in which they converted $9,100 principal and $18 in interest. We issued Southridge 91,175,304 common shares pursuant to Rule 144 based on an agreed conversion price of $0.0001 per share.
On October 3, 2012, SGI Group executed a partial debt to equity conversion of the $30,000 short-term promissory note originally dated August 25, 2011 and purchased on August 20, 2012 from Southridge, in which they converted $9,000 principal and $106 in interest. We issued SGI Group 182,124,200 common shares pursuant to Rule 144 based on an agreed conversion price of $0.00005 per share.
On October 4, 2012, Panache executed a partial debt to equity conversion of a $25,000 short-term promissory note dated February 28, 2012 in which they converted $6,600 principal. We issued Panache 120,000,000 common shares pursuant to Rule 144 based on an agreed conversion price of $0.000055 per share.